Tag: Psychedellux

This is Psychedellux – the week’s top psychedelic industry headlines. MindMed (NASDAQ: MNMD) shareholders have been taken on quite the trip over the last few days as the company uplisted from the Over The Counter Market to the big time at the NASDAQ. The stock jumped to over $5 a share in its last days […]

This is Psychedellux – the week’s top news for psychedelic stocks. Tryp Therapeutics (OTCQB: TRYPF) began trading this week on the OTCQB Venture Market under the symbol “TRYPF” and will continue to trade on the Canadian Securities Exchange under the symbol “TRYP”. Last week the company appointed Greg McKee as its Chief Executive Officer. Mydecine […]

This is Psychedellux, the week’s top news in psychedelic stocks. Mind Medicine (MindMed) Inc. (OTCQB: MMEDF) announced its annual 2020 financial results for the year ended December 31, 2020. At this time the company had no revenue to report. The net and comprehensive losses were $35.1 million for the year ending December 31, 2020. Its […]

This is Psychedellux, the week’s recap of psychedelic stock news.    COMPASS Pathways plc (Nasdaq: CMPS) said it has been granted two new patents. These patents cover oral formulations of COMPASS’s synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD).   Psychedelics-inspired biotech and life sciences company Mydecine Innovations […]

This is Psychedellux – the week’s top news in the psychedelics industry.  Initiative 81 in Washington DC, the Entheogenic Plant and Fungus Policy Act of 2020, became law. Initiative 81 changed DC law to make the enforcement of laws against those using plant and fungi medicines among the lowest law enforcement priorities. The ballot measure […]

This is Psychedellux, the week’s top news in the psychedelic industry Psychedelic medicine company Compass Pathways plc (Nasdaq: CMPS) reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business. Compass delivered a net loss for the quarter ending in December 2020 was $18.8 million, […]

Psychedelic medicine biotech company MindMed (OTCQB: MMEDF) said it will acquire HealthMode for roughly C41 million. HealthMode is a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring. The acquisition will give MindMed access to HealthMode’s Intellectual Property, platforms for […]